c-Met/HGFR

Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.

Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity .

Entacapone acid (AG 1290) is a selective and reversible inhibitor of catechol-O-methyltransferase(COMT).

BPI-9016M, an oral c-Met/AXL inhibitor, curbs growth and spread of lung cancer.

MET kinase-IN-2, a selective and potent MET kinase inhibitor, demonstrates oral bioavailability and exhibits an IC50 value of 7.4 nM.

MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an

Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (

TAM&Met-IN-1 inhibits AXL, MER, TYRO3 with IC50s 6.1, 13.2, 21.6 nM, respectively, for cancer research.

Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.

c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.

c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.

Juvenile hormone B 3 (Juvenile hormone III bisepoxide) (mixture of diastereomers) is a sesquiterpenoid hormone. It can be isolated from the corpora allata (CA) of higher dipteran insects such as fruit flies and Drosophila melanogaster. This hormone exhibits anti-metamorphic activity and induces the expression of Kr-h1 by directly interacting with juvenile hormone (JH) receptors (Met and Gce). Juvenile hormone B 3 (mixture of diastereomers) is applicable in insect lethality studies.

c-Met ligand-Linker Conjugate 2 is a synthetic target protein ligand-linker complex used in the synthesis of PROTACs, such as PROTACc-Met degrader-6. PROTACc-Met degrader-6 is a c-Met PROTAC degrader that exhibits antitumor activity.

BMS-748730, also known as 4′-Hydroxy Dasatinib, is a Dasatinib metabolite.

KIN-8741 is a highly selective and orally active Type IIb c-Met inhibitor. It exhibits broad-spectrum activity against c-Met kinase mutations. KIN-8741 demonstrates antitumor activity in non-small cell lung cancer models with MET gene amplification and exon 14 deletion. It is applicable in research on c-Met-driven cancers, particularly advanced tumors harboring MET exon 14 skipping mutations and acquired resistance mutations.

KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.

D6808: selective c-Met inhibitor, IC50=2.9 nM, induces apoptosis and cell cycle arrest, for NSCLC/gastric cancer research.